Market Overview

Sanofi, Pozen Announce Exclusive License Deal for Commercialization of PA8140/PA32540 Tablets in US

Related SNY
Prestige Brands Gains on Product Acquisition News - Analyst Blog
Good News for BioMarin - Analyst Blog
Novo Nordisk Upgraded to 'Buy' (Fox Business)
Related POZN
Pozen Submits Final Study Report for PA8140/PA32540 Phase 1 Study on Schedule
Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest EPS Estimates

Sanofi US (NYSE: SNY) and POZEN Inc. (NASDAQ: POZN) announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor (PPI), and enteric-coated (EC) aspirin in a single tablet ("PA"), PA8140 and PA32540. Under the terms of the agreement, Sanofi will have exclusive rights to commercialize all PA combinations that contain 325 mg or less of enteric-coated aspirin in the United States. POZEN will receive an upfront payment of $15MM and will be eligible for pre-commercial milestone payments of up to $20MM and other future milestone payments and royalties on product sales.

Posted-In: News FDA

 

Most Popular

Related Articles (POZN + SNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free